Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02714959
Other study ID # 1510112713
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2016
Est. completion date June 12, 2019

Study information

Verified date September 2021
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether low-dose IL-2 is effective in refractory autoimmune encephalitis.


Description:

Autoimmune encephalitis is a recently recognized etiology of encephalitis which is mediated by various autoantibodies targeting neural cells or synapses. The responses to immunotherapy is generally good, considerable proportion of patients with autoimmune encephalitis have unfavorable clinical outcomes. Recently, depletion of regulatory T cell (Treg cell) is reported in variable autoimmune diseases and multiple studies have shown that low-dose interleukin-2(IL-2) specifically activates Treg cells to control autoimmunity and inflammation. Protocol: This study is a single arm open-label study assessing clinical responses to the administration of low-dose IL-2 in autoimmune encephalitis patients who are refractory to first- and second-line immunotherapy. Objective: To assess the efficacy of low-dose IL-2 in autoimmune encephalitis, resistant to first- and second- line immunotherapy. Methods: This is a single arm open-label study. Each patients will receive four cycles of subcutaneous Proleukin (Interleukin-2, IL-2) (Week-1; 1.5 million IU (MIU)/d from Day-1 to Day-5, Week-3, -6, -9; 3MIU/d from Day-1 to Day-5) in the hospital. The patients will be followed up for 3 months (Week-21). Primary outcome - clinical efficacy by modified Rankin Scale Secondary outcome - Immunologic follow-up of Treg cells before, during, and after IL-2 therapy, quality of life, cognitive function, side effect of low-dose IL-2


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 12, 2019
Est. primary completion date June 12, 2019
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - Age > 18 years - Clinical diagnosis of autoimmune encephalitis - Positive for autoantibody (serum and or CSF) : NMDAR, anti-leucine-rich glioma inactivated-1(LGI-1), contactin-associated protein-like 2 (CASPR2), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) 1, AMPA2, GABAB-R, anti-Hu, -Yo, -Ri, -Ma2, -CV2/collapsing response mediator protein 5 (CRMP5), -amphiphysin, or glutamic acid decarboxylase (GAD) - Refractory to first-line (high-dose steroid or intravenous immunoglobulin) and second line (rituximab or cyclophosphamide) immunotherapy - Written informed consent form. Exclusion Criteria: - low hemoglobin <8.0 g/dL, absolute neutrophil count<1600/mm3, lymphocytes <600/mm3, platelets <140,000/mm3 - heart failure (= grade III NYHA), hepatic insufficiency (aspartate amino transferase >200 IU/L, amino alanine transferase, >200 IU/L), or lung failure - Positive for HIV serology, active hepatitis B - Significant abnormality in chest X-ray other than these linked to the diseases under investigation - Infection - Other progressive neurological degenerative disease. - Poor venous access not allowing repeated blood tests - pregnant or lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Proleukin


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

References & Publications (6)

Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, Lacour JP, Passeron T. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014 Jul;150(7):748-51. doi: 10.1001/jamadermatol.2014.504. — View Citation

Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8. — View Citation

Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, Riemekasten G. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21. — View Citation

Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015 May;15(5):283-94. doi: 10.1038/nri3823. Epub 2015 Apr 17. Review. — View Citation

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26. — View Citation

Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change of modified Rankin scale Week 0,12
Secondary The change of percentage of regulatory T (Treg) cells Week 1, 3, 5, 9, 12, 21
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Week 1, 3, 5, 9, 12, 21
Secondary Quality of Life in Epilepsy Inventory (QOLIE)-31 Quality of Life in Epilepsy Inventory (QOLIE)-31 Week 21
Secondary Beck Depression Inventory (BDI) Beck Depression Inventory (BDI) Week 21
Secondary Cognitive function Mini-mental state examination (MMSE) Week 21
See also
  Status Clinical Trial Phase
Completed NCT02538094 - tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis N/A
Completed NCT00381433 - Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid Phase 1
Completed NCT00031486 - Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir Phase 3
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Completed NCT02906631 - Epidemiology and Prognosis of Encephalitis in Intensive Care
Completed NCT02367664 - A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants Phase 3
Completed NCT00314132 - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Phase 3
Terminated NCT00927953 - Treatment of West Nile Virus With MGAWN1 Phase 2
Recruiting NCT05393492 - Regulating Emotions and Behaviors After Brain Injury N/A
Terminated NCT04361344 - Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection N/A
Recruiting NCT04460599 - Neurological Features During COVID19
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Completed NCT01041573 - Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population Phase 3
Completed NCT01092507 - A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Phase 3
Not yet recruiting NCT04722328 - Establishment of Prevention and Control System of Central Nervous System Infection
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Not yet recruiting NCT06368648 - CoMind Early Feasibility Study
Completed NCT02526550 - Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX Phase 4
Completed NCT01694524 - Nervous System Infections Among Patients With Febrile Seizure N/A
Completed NCT04080921 - Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis Phase 1/Phase 2